Skip to main content
Livermore
Livermore
ZHEN

Ikarian Capital, LLC

SEC CIK
0001778253
Latest filing
Aug 14, 2026

Holdings in Q4 2022

Holdings as of Dec 31, 2022, filed Feb 14, 2023. Long positions only; changes compare share counts with Q3 2022.

Institution overview
Positions
67
+2 vs. Q3 2022
Portfolio value
$241.0M
+$40.6M (+20.3%) vs. Q3 2022
Filed
Feb 14, 2023
SEC
Holdings of Ikarian Capital, LLC in Q4 2022
SecurityClassSharesValue% of portfolioShare changeActionHistory
RXDXPrometheus Biosciences, Inc.COM288,926$31.8M13.2%+57,745+25.0%AddedHistory
IMVTImmunovant, Inc.COM966,700$17.2M7.1%+155,000+19.1%AddedHistory
PCVXVaxcyte, Inc.COM250,000$12.0M5.0%+250,000NewHistory
CLDXCelldex Therapeutics, Inc.COM NEW267,476$11.9M4.9%−50,000−15.7%ReducedHistory
ESPREsperion Therapeutics, Inc.COM1,891,147$11.8M4.9%−240,000−11.3%ReducedHistory
BHVNBiohaven Ltd.COM837,500$11.6M4.8%+837,500NewHistory
HZNPHorizon Therapeutics Public Ltd CoSHS89,219$10.2M4.2%+15,000+20.2%AddedHistory
ATXSAstria Therapeutics, Inc.COM675,176$10.1M4.2%−24,264−3.5%ReducedHistory
ISEEIVERIC bio, Inc.COM377,021$8.07M3.3%−601,762−61.5%ReducedHistory
TERNTerns Pharmaceuticals, Inc.COM737,319$7.51M3.1%−166,800−18.4%ReducedHistory
Bellus Health Inc New07987C204COM NEW885,334$7.28M3.0%+35,200+4.1%Added–
VRNAVerona Pharma plcSPONSORED ADS255,131$6.67M2.8%−60,000−19.0%ReducedHistory
XENEXenon Pharmaceuticals Inc.COM160,486$6.33M2.6%00.0%UnchangedHistory
DCPHDeciphera Pharmaceuticals, Inc.COM367,119$6.02M2.5%−125,156−25.4%ReducedHistory
ETNB89bio, Inc.COM454,000$5.78M2.4%+254,000+127.0%AddedHistory
BLUEbluebird bio, Inc.COM812,628$5.62M2.3%+350,000+75.7%AddedHistory
BTAIQBioXcel Therapeutics, Inc.COM250,000$5.37M2.2%+250,000NewHistory
ACADAcadia Pharmaceuticals IncCOM325,000$5.17M2.1%00.0%UnchangedHistory
MRTXMirati Therapeutics, Inc.COM108,100$4.90M2.0%+108,100NewHistory
ALTAltimmune, Inc.COM NEW273,432$4.50M1.9%−198,622−42.1%ReducedHistory
KZRKezar Life Sciences, Inc.COM629,986$4.44M1.8%−98,600−13.5%ReducedHistory
TCONTracon Pharmaceuticals, Inc.COM NEW2,765,530$4.12M1.7%00.0%UnchangedHistory
ARDXArdelyx, Inc.COM1,378,825$3.93M1.6%−1,800,000−56.6%ReducedHistory
JBIOJade Biosciences, Inc.COM127,921$3.75M1.6%−72,079−36.0%ReducedHistory
SRPTSarepta Therapeutics, Inc.COM28,324$3.67M1.5%+11,515+68.5%AddedHistory
SGENSeagen Inc.COM25,000$3.21M1.3%+25,000NewHistory
RCUSArcus Biosciences, Inc.COM137,987$2.85M1.2%+137,987NewHistory
SAGESage Therapeutics, Inc.COM67,805$2.59M1.1%−90,000−57.0%ReducedHistory
MRUSMerus N.V.COM156,000$2.41M1.0%+156,000NewHistory
VKTXViking Therapeutics, Inc.COM203,156$1.91M0.8%−260,000−56.1%ReducedHistory
MISTMilestone Pharmaceuticals Inc.COM460,416$1.82M0.8%−395,200−46.2%ReducedHistory
PRQRProQR Therapeutics N.V.SHS EURO422,625$1.56M0.6%+422,625NewHistory
ABOSAcumen Pharmaceuticals, Inc.COM254,945$1.38M0.6%−95,055−27.2%ReducedHistory
ARK ETF Tr00214Q302GENOMIC REV ETF46,462$1.31M0.5%−50,000−51.8%Reduced–
LYRALyra Therapeutics, Inc.COM343,685$1.08M0.4%00.0%UnchangedHistory
ICPTIntercept Pharmaceuticals, Inc.COM85,200$1.05M0.4%00.0%UnchangedHistory
PNTPOINT Biopharma Global Inc.COM139,565$1.02M0.4%−310,841−69.0%ReducedHistory
CMMBChemomab Therapeutics Ltd.SPONSORED ADS313,392$1.00M0.4%+67,496+27.4%AddedHistory
IMUXImmunic, Inc.COM650,000$910.0K0.4%+650,000NewHistory
COGTCogent Biosciences, Inc.COM62,766$725.6K0.3%−100,000−61.4%ReducedHistory
OCULOcular Therapeutix, IncCOM200,000$562.0K0.2%−65,000−24.5%ReducedHistory
ELDNEledon Pharmaceuticals, Inc.COM221,830$514.6K0.2%00.0%UnchangedHistory
TARAProtara Therapeutics, Inc.COM STK188,664$505.6K0.2%00.0%UnchangedHistory
AUTLAutolus Therapeutics plcSPON ADS260,087$494.2K0.2%00.0%UnchangedHistory
IMTXImmatics N.V.SHS49,031$427.1K0.2%00.0%UnchangedHistory
ANEBAnebulo Pharmaceuticals, Inc.COM156,203$374.9K0.2%00.0%UnchangedHistory
OKUROnKure Therapeutics, Inc.COM155,819$363.1K0.2%00.0%UnchangedHistory
PRAXPraxis Precision Medicines, Inc.COM150,000$357.0K0.1%+150,000NewHistory
XFORX4 Pharmaceuticals, IncCOM349,133$346.7K0.1%−219,479−38.6%ReducedHistory
Bellicum Pharmaceuticals, Inc079481404COM NEW448,101$322.6K0.1%00.0%Unchanged–
BCLIBrainstorm Cell Therapeutics Inc.COM NEW189,935$311.5K0.1%00.0%UnchangedHistory
CABACabaletta Bio, Inc.COM30,286$280.1K0.1%−138,337−82.0%ReducedHistory
BIIBBiogen Inc.COM962$266.4K0.1%−10,000−91.2%ReducedHistory
SYBXSynlogic, Inc.COM306,757$233.1K0.1%00.0%UnchangedHistory
RLMDRelmada Therapeutics, Inc.COM65,491$228.6K0.1%+65,491NewHistory
CNTBConnect Biopharma Holdings LtdADS219,501$190.5K0.1%00.0%UnchangedHistory
Aslan Pharmaceuticals Ltd04522R101ADS820,455$151.4K0.1%00.0%Unchanged–
ARK Innovation ETF00214Q104ETF4,519$141.2K0.1%00.0%Unchanged–
STSASatsuma Pharmaceuticals, Inc.COM136,059$122.5K0.1%00.0%UnchangedHistory
DSGNDesign Therapeutics, Inc.COM11,568$118.7K<0.1%+11,568NewHistory
FNCHFinch Therapeutics Group, Inc.COM237,553$114.0K<0.1%00.0%UnchangedHistory
SPPISpectrum Pharmaceuticals IncCOM176,980$65.2K<0.1%00.0%UnchangedHistory
CRBPCorbus Pharmaceuticals Holdings, Inc.COM397,168$43.9K<0.1%00.0%UnchangedHistory
MDGLMadrigal Pharmaceuticals, Inc.COM75$21.8K<0.1%+75NewHistory
GOSSGossamer Bio, Inc.COM6,100$13.2K<0.1%−604,307−99.0%ReducedHistory
Erytech Pharma29604W108SPONSORED ADR3,019$1.19K<0.1%00.0%Unchanged–
KDNYChinook Therapeutics, Inc.COM283,464$00.0%00.0%UnchangedHistory

Options (16)

Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.

Option positions of Ikarian Capital, LLC in Q4 2022
SecurityClassPutsCalls
MDGLMadrigal Pharmaceuticals, Inc.COM$87.1M–
State Street SPDR S&P Biotech ETF78464A870ETF$8.30M$8.30M
KRYSKrystal Biotech, Inc.COM$13.1M–
RXDXPrometheus Biosciences, Inc.COM–$11.0M
ALTAltimmune, Inc.COM NEW–$9.50M
ESPREsperion Therapeutics, Inc.COM–$8.08M
RETAReata Pharmaceuticals IncCL A$7.64M–
RCUSArcus Biosciences, Inc.COM$5.85M–
VRNAVerona Pharma plcSPONSORED ADS–$5.23M
ARVNArvinas, Inc.COM–$3.42M
ATXSAstria Therapeutics, Inc.COM–$2.55M
GERNGeron CorpCOM$363.0K$1.57M
DSGNDesign Therapeutics, Inc.COM$497.6K$8.21K
BIIBBiogen Inc.COM–$498.5K
IMVTImmunovant, Inc.COM–$465.1K
TCDATricida, Inc.COM–$22.3K

Sold out since Q3 2022 (11)

Positions held at the end of Q3 2022 that are gone from this filing.

Positions of Ikarian Capital, LLC sold out since Q3 2022
SecurityClassShares in Q3 2022Value in Q3 2022% of portfolio in Q3 2022History
CERECerevel Therapeutics Holdings, Inc.COM178,100$5.03M2.5%History
SCPHscPharmaceuticals Inc.COM479,383$3.13M1.6%History
RVNCRevance Therapeutics, Inc.COM100,000$2.70M1.3%History
CINCCinCor Pharma, Inc.COM45,100$1.48M0.7%History
MCRBSeres Therapeutics, Inc.COM131,310$843.0K0.4%History
RCORRenovacor, Inc.COM288,119$725.0K0.4%History
ALNYAlnylam Pharmaceuticals, Inc.COM2,800$560.0K0.3%History
CLVSClovis Oncology, Inc.COM361,518$430.0K0.2%History
Stealth Biotherapeutics Corp85789A105SPONSORED ADS435,516$134.0K0.1%–
RETAReata Pharmaceuticals IncCL A4,064$102.0K0.1%History
IVAInventiva S.A.ADS13,236$48.0K<0.1%History